Therapeutics News and Research

RSS

Study provides a new target for therapeutic intervention in Parkinson's disease

In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.

14 Nov 2021

Study reveals how certain cells drive immunotherapy resistance in ovarian cancer mouse model

Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.

12 Nov 2021

Study assesses whether medicinal mushrooms and Chinese herbs can help treat COVID-19

A novel study is assessing whether medicinal mushrooms and Chinese herbs provide therapeutic benefit in treating acute COVID-19 infection.

12 Nov 2021

NanoTCE technology shows promise for treatment of acute myeloid leukemia

Oncotarget published "Nanoparticle T cell engagers for the treatment of acute myeloid leukemia" which reported that Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%.

12 Nov 2021

Higher order protein catenation leads to the development of artificial antibodies

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

12 Nov 2021

Study may pave the way for a more personalized approach to COVID-19 diagnosis and treatment

Using some of the most advanced molecular sequencing tools available to evaluate COVID-19 rapid autopsy tissues, researchers have identified four major regulatory pathways, specific molecular effectors behind COVID-19 symptoms, and differences that drive diverging clinical courses among individual patients.

11 Nov 2021

New treatment for myocardial infarction using mussel adhesive proteins

Patients not only have to fight their diseases but also must deal with the pain – the more severe the condition, the more painful the injections.

11 Nov 2021

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.

11 Nov 2021

New therapy harnesses "dancing molecules" to reverse paralysis, repair tissue after spinal cord injuries

Northwestern University investigators have developed a new injectable therapy that harnesses "dancing molecules" to reverse paralysis and repair tissue after severe spinal cord injuries.

11 Nov 2021

New target for drug development could fill a major gap in depression treatment

Vanderbilt researchers found that ketamine's rapid antidepressant action is due to specific synaptic effects.

10 Nov 2021

Newly discovered RNA molecule protects mice from emerging SARS-CoV-2 variants

Researchers at Yale School of Medicine have discovered that an RNA molecule that stimulates the body's early antiviral defense system can protect mice from a range of emerging SARS-CoV-2 variants.

10 Nov 2021

New biomarkers could help determine synaptic damage and neurodegeneration in Alzheimer's

Alzheimer's disease is the main neurodegenerative disease in old people for which there is no treatment or efficient prevention yet.

10 Nov 2021

Stenoparib effectively inhibits SARS-CoV-2 variants in vitro

A new study assesses the antiviral activity of stenoparib against four SARS-CoV-2 strains.

10 Nov 2021

Mechanisms and strategies for antibody binding and escape in SARS-CoV-2

A new study investigated the mechanisms for binding and strategies to escape several hNAbs used by SARS-CoV-2 strains through molecular simulations.

10 Nov 2021

Retinoid therapy improves vision in mice with Usher syndrome

Using data generated from patients and mice with genetic mutation for the disorder Usher syndrome, researchers from the University of Maryland School of Medicine, the National Institutes of Health's National Eye Institute, and National Institute on Deafness and Other Communication Disorders, documented the natural history of vision impairment in patients and identified the cell mechanism behind progressive vision loss.

9 Nov 2021

BioIVT to highlight the use of SCHH model to investigate drug-drug interaction of bempedoic acid

BioIVT, a leading provider of research models and services for drug and diagnostic development, is hosting a webinar in which researchers will discuss how they used a sandwich-cultured human hepatocyte (SCHH) model to investigate the drug-drug interaction (DDI) potential of bempedoic acid, a drug that was recently approved to treat hypercholesterolemia.

9 Nov 2021

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

9 Nov 2021

Early or late bedtimes may cause adverse consequences for cardiovascular health

Going to sleep between 10:00 and 11:00 pm is associated with a lower risk of developing heart disease compared to earlier or later bedtimes, according to a study published today in European Heart Journal – Digital Health, a journal of the European Society of Cardiology.

9 Nov 2021

SBIR grant awarded to develop treatment for alcoholic liver disease-associated hepatorenal syndrome

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine and MitoPower LLC were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.

9 Nov 2021

COVID-19 drug candidate with wide-ranging antiviral activity

A new study investigated the antiviral activity and mechanism of action of Brilacidin against multiple human coronaviruses.

9 Nov 2021

Therapeutics News and Research

Study provides a new target for therapeutic intervention in Parkinson's disease

Study reveals how certain cells drive immunotherapy resistance in ovarian cancer mouse model

Study assesses whether medicinal mushrooms and Chinese herbs can help treat COVID-19

NanoTCE technology shows promise for treatment of acute myeloid leukemia

Higher order protein catenation leads to the development of artificial antibodies

Study may pave the way for a more personalized approach to COVID-19 diagnosis and treatment

New treatment for myocardial infarction using mussel adhesive proteins

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

New therapy harnesses "dancing molecules" to reverse paralysis, repair tissue after spinal cord injuries

New target for drug development could fill a major gap in depression treatment

Newly discovered RNA molecule protects mice from emerging SARS-CoV-2 variants

New biomarkers could help determine synaptic damage and neurodegeneration in Alzheimer's

Stenoparib effectively inhibits SARS-CoV-2 variants in vitro

Mechanisms and strategies for antibody binding and escape in SARS-CoV-2

Retinoid therapy improves vision in mice with Usher syndrome

BioIVT to highlight the use of SCHH model to investigate drug-drug interaction of bempedoic acid

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Early or late bedtimes may cause adverse consequences for cardiovascular health

SBIR grant awarded to develop treatment for alcoholic liver disease-associated hepatorenal syndrome

COVID-19 drug candidate with wide-ranging antiviral activity

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News